A Fundamental Shift in Cancer Care
At Aulos, we’re on a journey to revolutionize cancer patient care through the development of an immune-activating antibody therapeutic that we believe will transform the treatment of cancer. We’re taking on the toughest challenges in immuno-oncology by leveraging artificial intelligence to design a human monoclonal antibody that binds to the portion of IL-2 that interacts with the CD25 receptor subunit on regulatory T cells and the vasculature. We believe this therapeutic approach can shift interleukin-2 activity toward immune activation and away from immune suppression, and prevent the toxic side effects of IL-2, including vascular leak syndrome and pulmonary edema.
Abstracts and Publications
FEATURE
AU-007, a Human Monoclonal Antibody (mAb) That Binds to IL-2 and Inhibits CD25 Binding, Plus Low-Dose Aldesleukin, in Advanced Solid Tumors: Phase 2 Update
Latest News
AU-007: An Investigational Product Candidate
Aulos has initiated the Phase 2 portion of its Phase 1/2 clinical trial of AU-007 in patients with unresectable locally advanced or metastatic solid tumor cancers. The first expansion cohorts will focus on melanoma and renal cell carcinoma.
